Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice

Yan Li(Sanford Burnham Prebys Medical Discovery Institute), Roberto Tinoco(Sanford Burnham Prebys Medical Discovery Institute), Lisa Elmeń(Sanford Burnham Prebys Medical Discovery Institute), Igor Šegota(Sanford Burnham Prebys Medical Discovery Institute), Yibo Xian(University of Nebraska–Lincoln), Yu Fujita(Sanford Burnham Prebys Medical Discovery Institute), Avinash Sahu(University of Maryland, College Park), Raphy Zarecki(Tel Aviv University), Kerrie L. Marie(National Institutes of Health), Yongmei Feng(Sanford Burnham Prebys Medical Discovery Institute), Ali Khateb(Technion – Israel Institute of Technology), Dennie T. Frederick(Harvard University), Shiri K. Ashkenazi(Technion – Israel Institute of Technology), Hyungsoo Kim(Sanford Burnham Prebys Medical Discovery Institute), Eva Guijarro Perez(National Institutes of Health), Chi-Ping Day(National Institutes of Health), Rafael R. Segura Muñoz(University of Nebraska–Lincoln), Robert Schmaltz(University of Nebraska–Lincoln), Shibu Yooseph(University of Central Florida), Miguel A. Tam(BioLegend (United States)), Tongwu Zhang(National Cancer Institute), Emily Avitan‐Hersh(Technion – Israel Institute of Technology), Lihi Tzur(Rambam Health Care Campus), Shoshana Roizman(Rambam Health Care Campus), Ilanit Boyango(Rambam Health Care Campus), Gil Bar‐Sela(Technion – Israel Institute of Technology), Amir Orian(Technion – Israel Institute of Technology), Randal J. Kaufman(Sanford Burnham Prebys Medical Discovery Institute), Marcus Bosenberg(Yale University), Colin R. Goding(Ludwig Cancer Research), Bas Baaten(Sanford Burnham Prebys Medical Discovery Institute), Mitchell P. Levesque(University of Zurich), Reinhard Dummer(University of Zurich), Kevin M. Brown(National Cancer Institute), Glenn Merlino(National Institutes of Health), Eytan Ruppin(National Institutes of Health), Keith T. Flaherty(Harvard University), Amanda E. Ramer‐Tait(University of Nebraska–Lincoln), Tao Long(Sanford Burnham Prebys Medical Discovery Institute), Scott N. Peterson(Sanford Burnham Prebys Medical Discovery Institute), Linda M. Bradley(Sanford Burnham Prebys Medical Discovery Institute), Ze’ev A. Ronai(Technion – Israel Institute of Technology)
Nature Communications
April 2, 2019
Cited by 226Open Access
Full Text

Abstract

Abstract Accumulating evidence points to an important role for the gut microbiome in anti-tumor immunity. Here, we show that altered intestinal microbiota contributes to anti-tumor immunity, limiting tumor expansion. Mice lacking the ubiquitin ligase RNF5 exhibit attenuated activation of the unfolded protein response (UPR) components, which coincides with increased expression of inflammasome components, recruitment and activation of dendritic cells and reduced expression of antimicrobial peptides in intestinal epithelial cells. Reduced UPR expression is also seen in murine and human melanoma tumor specimens that responded to immune checkpoint therapy. Co-housing of Rnf5 −/− and WT mice abolishes the anti-tumor immunity and tumor inhibition phenotype, whereas transfer of 11 bacterial strains, including B. rodentium , enriched in Rnf5 −/− mice, establishes anti-tumor immunity and restricts melanoma growth in germ-free WT mice. Altered UPR signaling, exemplified in Rnf5 −/− mice, coincides with altered gut microbiota composition and anti-tumor immunity to control melanoma growth.


Related Papers